nach oben

Erschienen in:

01.10.2014 | Original Article

Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children’s Oncology Group

verfasst von: Patrick Thompson, Heather E. Wheeler, Shannon M. Delaney, Rachel Lorier, Ulrich Broeckel, Meenakshi Devidas, Gregory H. Reaman, Kathleen Scorsone, Lillian Sung, M. Eileen Dolan, Stacey L. Berg

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We explored the impact of obesity, body composition, and genetic polymorphisms on the pharmacokinetics (PK) of daunorubicin in children with cancer.

Patients and methods

Patients ≤21 years receiving daunorubicin as an infusion of any duration <24 h for any type of cancer were eligible. Plasma drug concentrations were measured by high-performance liquid chromatography. Body composition was measured by dual-energy X-ray absorptiometry. Obesity was defined as a BMI >95 % for age or as body fat >30 %. NONMEM was used to perform PK model fitting. The Affymetrix DMET chip was used for genotyping. The impact of genetic polymorphisms was investigated using SNP/haplotype association analysis with estimated individual PK parameters.

Results

A total of 107 subjects were enrolled, 98 patients had PK sampling, and 50 patients underwent DNA analysis. Population estimates for daunorubicin clearance and volume of distribution were 116 L/m²/h ± 14 % and 68.1 L/m² ± 24 %, respectively. Apparent daunorubicinol clearance and volume of distribution were 26.8 L/m²/h ± 5.6 % and 232 L/m² ± 10 %, respectively. No effect of body composition or obesity was observed on PK. Forty-four genes with variant haplotypes were tested for association with PK. FMO3-H1/H3 genotype was associated with lower daunorubicin clearance than FMO3-H1/H1, p = 0.00829. GSTP1*B/*B genotype was also associated with lower daunorubicin clearance compared to GSTP1*A/*A, p = 0.0347. However, neither of these associations was significant after adjusting for multiple testing by either Bonferroni or false discovery rate correction.

Conclusions

We did not detect an effect of body composition or obesity on daunorubicin PK. We found suggestive associations between FMO3 and GSTP1 haplotypes with daunorubicin PK that could potentially affect efficacy and toxicity.

Nur mit Berechtigung zugänglich

Robert J (1998) Anthracyclines. In: Grochow LB, Ames MM (eds) A clinician’s guide to chemotherapy pharmacokinetics and pharmacodynamics. Williams and Wilkins, Baltimore, pp 93–173

Kuffel MJ, Ames MM (1995) Comparative resistance of idarubicin, doxorubicin and their C-13 alcohol metabolites in human MDR1 transfected NIH-3T3 Cells. Cancer Chemother Pharmacol 36:223–226PubMedCrossRef

Boucek RJ Jr, Olson RD, Boucek DE et al (1987) The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions. J Biol Chem 262:15851–15856PubMed

Olson RD, Mushlin PS, Brenner DE et al (1988) Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci U S A 85:3585–3589PubMedCrossRefPubMedCentral

Cusack BJ, Young SP, Driskell J et al (1993) Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. Cancer Chemother Pharmacol 32:53–58PubMedCrossRef

Mushlin PS, Cusack BJ, Boucek RJ Jr et al (1993) Time-related increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function. Br J Pharmacol 110:975–982PubMedCrossRefPubMedCentral

Stewart DJ, Grewaal D, Green RM et al (1993) Concentrations of doxorubicin and its metabolites in human autopsy heart and other tissues. Anticancer Res 13:1945–1952PubMed

Forrest GL, Gonzalez B, Tseng W et al (2000) Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. Cancer Res 60:5158–5164PubMed

Wang GX, Wang YX, Zhou XB et al (2001) Effects of doxorubicinol on excitation–contraction coupling in guinea pig ventricular myocytes. Eur J Pharmacol 423:99–107PubMedCrossRef

10.

Olson LE, Bedja D, Alvey SJ et al (2003) Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1. Cancer Res 63:6602–6606PubMed

11.

Lal S, Mahajan A, Chen WN et al (2010) Pharmacogenetics of target genes across doxorubicin disposition pathway: a review. Curr Drug Metab 11:115–128PubMedCrossRef

12.

Ueda K, Cardarelli C, Gottesman MM et al (1987) Expression of a full-length cDNA for the human “MDR1” gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A 84:3004–3008PubMedCrossRefPubMedCentral

13.

Sharma R, Singhal SS, Cheng J et al (2001) RLIP76 is the major ATP-dependent transporter of glutathione-conjugates and doxorubicin in human erythrocytes. Arch Biochem Biophys 391:171–179PubMedCrossRef

14.

Okabe M, Unno M, Harigae H et al (2005) Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem Biophys Res Commun 333:754–762PubMedCrossRef

15.

Lal S, Sandanaraj E, Wong ZW et al (2008) CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. Cancer Sci 99:2045–2054PubMedCrossRef

16.

Sandanaraj E, Lal S, Selvarajan V et al (2008) PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients. Clin Cancer Res 14:7116–7126PubMedCrossRef

17.

Rocha JC, Cheng C, Liu W et al (2005) Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 105:4752–4758PubMedCrossRefPubMedCentral

18.

Pander J, Gelderblom H, Guchelaar HJ (2007) Insights into the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anticancer drugs. Expert Opin Pharmacother 8:1197–1210PubMedCrossRef

19.

Lange BJ, Gerbing RB, Feusner J et al (2005) Mortality in overweight and underweight children with acute myeloid leukemia. JAMA 293:203–211PubMedCrossRef

20.

Hijiya N, Panetta JC, Zhou Y et al (2006) Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. Blood 108:3997–4002PubMedCrossRefPubMedCentral

21.

Palle J, Frost BM, Peterson C et al (2006) Doxorubicin pharmacokinetics is correlated to the effect of induction therapy in children with acute myeloid leukemia. Anticancer Drugs 17:385–392PubMedCrossRef

22.

Thompson PA, Rosner GL, Matthay KK, et al. (2008) Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser pediatric research network study. Cancer Chemother Pharmacol

23.

Berg S, Cowan K, Balis F et al (1994) Pharmacokinetics of Taxol and Doxorubicin administered alone and in combination by continuous 72-hour infusion. J Natl Cancer Inst 86:143–145PubMedCrossRef

24.

Dobbs N, James C (1987) Estimation of doxorubicin and doxorubicinol by high performance liquid chromatography and advanced automated sample processor. J Chromatogr Biomed Appl 420:184–188CrossRef

25.

Hempel G, Relling MV, de Rossi G et al (2010) Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol. Pediatr Blood Cancer 54:355–360PubMedCrossRef

26.

Purcell S, Neale B, Todd-Brown K et al (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81:559–575PubMedCrossRefPubMedCentral

27.

Callies S, de Alwis DP, Mehta A et al (2004) Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979). Cancer Chemother Pharmacol 54:39–48PubMedCrossRef

28.

Mannervik B, Alin P, Guthenberg C et al (1985) Identification of three classes of cytosolic glutathione transferase common to several mammalian species: correlation between structural data and enzymatic properties. Proc Natl Acad Sci U S A 82:7202–7206PubMedCrossRefPubMedCentral

29.

O’Brien M, Kruh GD, Tew KD (2000) The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance. J Pharmacol Exp Ther 294:480–487PubMed

30.

Hayes JD, Pulford DJ (1995) The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30:445–600PubMedCrossRef

31.

Marciniak P, Drobnik K, Ziemnicka K et al (2006) Transferase S-glutathione class pi gene (GSTP1) polymorphism in thyroid cancer patients. Endokrynol Pol 57:509–515PubMed

32.

Ali-Osman F, Akande O, Antoun G et al (1997) Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem 272:10004–10012PubMedCrossRef

33.

Romero A, Martin M, Oliva B, et al. (2011) Glutathione S-transferase P1 c.313A>G polymorphism could be useful in the prediction of doxorubicin response in breast cancer patients. Ann Oncol

34.

Dasgupta RK, Adamson PJ, Davies FE et al (2003) Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma. Blood 102:2345–2350PubMedCrossRef

35.

Sweeney C, McClure GY, Fares MY et al (2000) Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. Cancer Res 60:5621–5624PubMed

36.

Stoehlmacher J, Park DJ, Zhang W et al (2002) Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94:936–942PubMedCrossRef

37.

Hohaus S, Di Ruscio A, Di Febo A et al (2005) Glutathione S-transferase P1 genotype and prognosis in Hodgkin’s lymphoma. Clin Cancer Res 11:2175–2179PubMedCrossRef

38.

Stanulla M, Schaffeler E, Arens S et al (2005) GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemia. Int J Hematol 81:39–44PubMedCrossRef

39.

Ramos DL, Gaspar JF, Pingarilho M et al (2011) Genotoxic effects of doxorubicin in cultured human lymphocytes with different glutathione S-transferase genotypes. Mutat Res 724:28–34PubMedCrossRef

40.

Hisamuddin IM, Yang VW (2007) Genetic polymorphisms of human flavin-containing monooxygenase 3: implications for drug metabolism and clinical perspectives. Pharmacogenomics 8:635–643PubMedCrossRefPubMedCentral

41.

Soderberg MM, Haslemo T, Molden E, et al. (2012) Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients. Pharmacogenomics J

42.

Lal S, Wong ZW, Sandanaraj E et al (2008) Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Sci 99:816–823PubMedCrossRef

43.

Lal S, Wong ZW, Jada SR et al (2007) Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics 8:567–575PubMedCrossRef

Titel: Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children’s Oncology Group
verfasst von: Patrick Thompson
Heather E. Wheeler
Shannon M. Delaney
Rachel Lorier
Ulrich Broeckel
Meenakshi Devidas
Gregory H. Reaman
Kathleen Scorsone
Lillian Sung
M. Eileen Dolan
Stacey L. Berg
Publikationsdatum: 01.10.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 4/2014
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-014-2535-4

Springer Medizin

Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children’s Oncology Group